Rapid Diagnosis of Tuberculosis with the Xpert MTB/RIF Assay in High Burden Countries: A Cost-Effectiveness Analysis
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Xpert MTB/RIF (Xpert) is a promising new rapid diagnostic technology for tuberculosis (TB) that has characteristics that suggest large-scale roll-out. However, because the test is expensive, there are concerns among TB program managers and policy makers regarding its affordability for low- and middle-income settings. METHODS AND FINDINGS: We estimate the impact of the introduction of Xpert on the costs and cost-effectiveness of TB care using decision analytic modelling, comparing the introduction of Xpert to a base case of smear microscopy and clinical diagnosis in India, South Africa, and Uganda. The introduction of Xpert increases TB case finding in all three settings; from 72%-85% to 95%-99% of the cohort of individuals with suspected TB, compared to the base case. Diagnostic costs (including the costs of testing all individuals with suspected TB) also increase: from US$28-US$49 to US$133-US$146 and US$137-US$151 per TB case detected when Xpert is used "in addition to" and "as a replacement of" smear microscopy, respectively. The incremental cost effectiveness ratios (ICERs) for using Xpert "in addition to" smear microscopy, compared to the base case, range from US$41-$110 per disability adjusted life year (DALY) averted. Likewise the ICERS for using Xpert "as a replacement of" smear microscopy range from US$52-$138 per DALY averted. These ICERs are below the World Health Organization (WHO) willingness to pay threshold. CONCLUSIONS: Our results suggest that Xpert is a cost-effective method of TB diagnosis, compared to a base case of smear microscopy and clinical diagnosis of smear-negative TB in low- and middle-income settings where, with its ability to substantially increase case finding, it has important potential for improving TB diagnosis and control. The extent of cost-effectiveness gain to TB programmes from deploying Xpert is primarily dependent on current TB diagnostic practices. Further work is required during scale-up to validate these findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapid Molecular Detection of Tuberculosis and Rifampin Resistance
Boehme, C. C., Nabeta, P., Hillemann, D., Nicol, M. P., Shenai, S., Krapp, F., Allen, J., Tahirli, R., Blakemore, R., Rustomjee, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907847 · Cited by 2,309 · cited 1×
“The Xpert MTB/RIF assay (referred to as Xpert in this article), is a real-time PCR assay that is a design-locked, all-within-cartridge test, and that has demonstrated high performance and could be deployed in a range of low- and middle-income settings [2,3].”
MethodSelf-citationBoehme, C. C., Nicol, M. P., Nabeta, P., Michael, J. S., Gotuzzo, E., Tahirli, R., Gler, M. T., Blakemore, R., Worodria, W., Gray, C., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60438-8 · Cited by 1,013
Self-citationTiming of Initiation of Antiretroviral Drugs during Tuberculosis Therapy
Abdool Karim, S. S., Naidoo, K., Grobler, A., Padayatchi, N., Baxter, C., Gray, A., Gengiah, T., Nair, G., Bamber, S., Singh, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0905848 · Cited by 666
Espinal, M. A., Kim, S. J., Suarez, P. G., Kam, K. M., Khomenko, A. G., Migliori, G. B., Baéz, J., Kochi, A., Dye, C., & Raviglione, M. C. (2000) · JAMA · doi:10.1001/jama.283.19.2537 · Cited by 507
HIV Infection and Multidrug‐Resistant Tuberculosis—The Perfect Storm
Wells, C. D., Cegielski, J. P., Nelson, L. J., Laserson, K. F., Holtz, T. H., Finlay, A., Castro, K. G., & Weyer, K. (2007) · The Journal of Infectious Diseases · doi:10.1086/518665 · Cited by 483
Microscopic-Observation Drug-Susceptibility Assay for the Diagnosis of TB
Moore, D. A. J., Evans, C. A. W., Gilman, R. H., Caviedes, L., Coronel, J., Vivar, A., Sanchez, E., Piñedo, Y., Saravia, J. C., Salazar, C., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055524 · Cited by 468
Shillcutt, S. D., Walker, D. G., Goodman, C. A., & Mills, A. J. (2009) · PharmacoEconomics · doi:10.2165/10899580-000000000-00000 · Cited by 207
van Cleeff, M., Kivihya-Ndugga, L., Meme, H., Odhiambo, J., & Klatser, P. (2005) · BMC Infectious Diseases · doi:10.1186/1471-2334-5-111 · Cited by 199
Menzies, D., Benedetti, A., Paydar, A., Royce, S., Pai, M., Burman, W., Vernon, A., & Lienhardt, C. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000150 · Cited by 194
Initial Drug Resistance and Tuberculosis Treatment Outcomes: Systematic Review and Meta-analysis
Lew, W., Pai, M., Oxlade, O., Martin, D., & Menzies, D. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-2-200807150-00008 · Cited by 187
Cost and cost-effectiveness of PPM-DOTS for tuberculosis control: evidence from India
Floyd, K., Arora, V. K., Murthy, K. J. R., Lönnroth, K., Singla, N., Akbar, Y. H., Zignol, M., & Uplekar, M. W. (2006) · Bulletin of the World Health Organization · doi:10.2471/blt.05.024109 · Cited by 122
Early Outcomes of MDR-TB Treatment in a High HIV-Prevalence Setting in Southern Africa
Seung, K. J., Omatayo, D. B., Keshavjee, S., Furin, J. J., Farmer, P. E., & Satti, H. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007186 · Cited by 122
Cost and cost-effectiveness of community-based care for tuberculosis in Cape Town, South Africa.
Sinanovic, E., Floyd, K., Dudley, L., Azevedo, V. D. S., Grant, R., & Maher, D. (2003) · PubMed · Cited by 95
Akksilp, S., Karnkawinpong, O., Wattanaamornkiat, W., Viriyakitja, D., Monkongdee, P., Sitti, W., Rienthong, D., Siraprapasiri, T., Wells, C. D., Tappero, J. W., et al. (2007) · Emerging infectious diseases · doi:10.3201/eid1307.061506 · Cited by 93
Cost-effectiveness of novel diagnostic tools for the diagnosis of tuberculosis.
Dowdy, D. W., O'Brien, M. A., & Bishai, D. M. (2008) · PubMed · Cited by 73
Cost and cost-effectiveness of community-based care for tuberculosis patients in rural Uganda.
Okello, D., Floyd, K., Adatu, F., Odeke, R., & Gargioni, G. (2003) · PubMed · Cited by 68
Dowdy, D. W., Lourenço, M. C. S., Cavalcante, S. C., Saraceni, V., King, B., Golub, J. E., Bishai, D. M., Durovni, B., Chaisson, R. E., & Dorman, S. E. (2008) · PLoS ONE · doi:10.1371/journal.pone.0004057 · Cited by 67
Varma, J. K., Nateniyom, S., Akksilp, S., Mankatitham, W., Sirinak, C., Sattayawuthipong, W., Burapat, C., Kittikraisak, W., Monkongdee, P., Cain, K. P., et al. (2009) · BMC Infectious Diseases · doi:10.1186/1471-2334-9-42 · Cited by 64
Is Scale-Up Worth It? Challenges in Economic Analysis of Diagnostic Tests for Tuberculosis
Dowdy, D. W., Cattamanchi, A., Steingart, K. R., & Pai, M. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1001063 · Cited by 62
Acuña-Villaorduña, C., Vassall, A., Henostroza, G., Seas, C., Guerra, H., Vásquez, L., Morcillo, N., Saravia, J. C., O’Brien, R., Perkins, M. D., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/590010 · Cited by 58
Self-citationPantoja, A. F., Lönnroth, K., Lal, S., Chauhan, L. S., Uplekar, M., Padma, M. R., Unnikrishnan, K. P., Jammy, G. R., Kumar, P. R., Sahu, S., et al. (2009) · PubMed · Cited by 48
Holtz, T. H., Kabera, G. M., Mthiyane, T., Zingoni, T., Nadesan, S., Ross, D., Allen, J., Chideya, S., Sunpath, H., & Rustomjee, R. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70057-3 · Cited by 48
Br, R., van Cleeff, M. R. A., Wa, G., Kivihya-Ndugga, L. E. A., Odhiambo, J. A., Kibuga, D., & Pr, K. (1998) · PubMed · Cited by 38
Cited by
Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults
Steingart, K. R., Schiller, I., Horne, D. J., Pai, M., Boehme, C. C., & Dendukuri, N. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009593.pub3 · Cited by 1,102
Self-citationDiagnostic point-of-care tests in resource-limited settings
Drain, P. K., Hyle, E. P., Noubary, F., Freedberg, K. A., Wilson, D., Bishai, W. R., Rodriguez, W., & Bassett, I. V. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70250-0 · Cited by 744
Pai, N. P., Vadnais, C., Denkinger, C., Engel, N., & Pai, M. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001306 · Cited by 593
Lawn, S. D., Mwaba, P., Bates, M., Piatek, A., Alexander, H., Marais, B. J., Cuevas, L. E., McHugh, T. D., Zijenah, L., Kapata, N., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70008-2 · Cited by 458
Theron, G., Zijenah, L., Chanda, D., Clowes, P., Rachow, A., Lesosky, M., Bara, W., Mungofa, S., Pai, M., Hoelscher, M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62073-5 · Cited by 433
Metadata
- Authors
- Vassall, A., van Kampen, S., Sohn, H., Michael, J. S., John, K. R., den Boon, S., Davis, J. L., Whitelaw, A., Nicol, M. P., Gler, M. T., Khaliqov, A., Zamudio, C., Perkins, M. D., Boehme, C. C., & Cobelens, F.
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-11-08
- Volume
- 8
- Issue
- 11
- Pages
- e1001120
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2004015348
- Cited by
- 313
- References
- 23
- FWCI
- 20.02
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.